(Q46640357)

23 December 2017

title

Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine (English)

1 reference

23 December 2017

0 references

0 references

Michael J Owens

1

1 reference

23 December 2017

Stan Krulewicz

2

1 reference

23 December 2017

Jeffrey S Simon

3

1 reference

23 December 2017

David V Sheehan

4

1 reference

23 December 2017

Michael E Thase

5

1 reference

23 December 2017

David J Carpenter

6

1 reference

23 December 2017

Susan J Plott

7

1 reference

23 December 2017

Charles B Nemeroff

8

1 reference

23 December 2017

language of work or name

English

0 references

publication date

16 April 2008

1 reference

23 December 2017

published in

Neuropsychopharmacology

1 reference

23 December 2017

volume

33

1 reference

23 December 2017

issue

13

1 reference

23 December 2017

page(s)

3201-3212

1 reference

23 December 2017

Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Effects of paroxetine and venlafaxine XR on heart rate variability in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Cerebrospinal fluid levels of amitriptyline, nortriptyline, imipramine and desmethylimipramine. Relationship to plasma levels and treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Imipramine and desipramine in plasma and spinal fluid: relationship to clinical response and serotonin metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

The burden of severe depression: a review of diagnostic challenges and treatment alternatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Treatment of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Pharmacological profile of antidepressants and related compounds at human monoamine transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Clinical efficacy of paroxetine in resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

Inhibition of P-glycoprotein by newer antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Differential physiological effects of a low dose and high doses of venlafaxine in major depression

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Evidence of the dual mechanisms of action of venlafaxine

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Haloperidol plasma levels and clinical response in paranoid schizophrenics

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Synergistic benefits of serotonin and noradrenaline reuptake inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Paroxetine binding to the rat norepinephrine transporter in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.47

7 January 2021

Identifiers

DOI

10.1038/NPP.2008.47

1 reference

23 December 2017

1 reference

23 December 2017